Pooled Analysis of the Prognostic and Predictive Effects of KRAS Mutation Status and KRAS Mutation Subtype in Early-Stage Resected Non–Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy
作者： Frances A Shepherd , Caroline Domerg , Pierre Hainaut , Pasi A Jänne , Jean-Pierre Pignon
关键词:
摘要: Purpose We undertook this analysis of KRAS mutation in four trials adjuvant chemotherapy (ACT) versus observation (OBS) to clarify the prognostic/predictive roles non–small-cell lung cancer (NSCLC). Methods was determined blinded fashion. Exploratory analyses were performed characterize relationships between status and subtype survival outcomes using a multivariable Cox model. Results Among 1,543 patients (763 OBS, 780 ACT), 300 had mutations (codon 12, n = 275; codon 13, 24; 14, 1). In OBS patients, there no prognostic difference for overall codon-12 (mutation v wild type [WT] hazard ratio [HR] 1.04; 95% CI, 0.77 1.40) or codon-13 (HR 1.01; 0.47 2.17) mutations. No significant benefit from ACT observed WT-KRAS (ACT HR 0.89; 0.76 P .15) 0.95; 0.67 1.35; .77); with mutations, deleterious 5.78; 2.06 t...
sci-hub.se 参考文章(41)
S. Rodenhuis, S. S. Wagenaar, W. J. Mooi, A. J. M. Boot, R. J. C. Slebos, P. C. Van Bodegom, S. G. Evers, J. L. Bos, Incidence and Possible Clinical Significance of K- ras Oncogene Activation in Adenocarcinoma of the Human Lung Cancer Research. ,vol. 48, pp. 5738- 5741 ,(1988)
G. I Meling, P Laurent-Puig, B. J Iacopetta, R Glaesener, O. P. F Clausen, F Al-Mulla, W Giaretti, V. J Bubb, A. F. P. M de Goeij, G Gaudernack, T Ohkusa, P Quirke, A Rapallo, N Hawkins, R Rosell, T. O Rognum, S. N Andersen, R Smith, J Costa, R Ward, I Hoffmann, T Fujimori, D Cunningham, D Morton, C. T Croke, J Oates, X. F Sun, S Bell, P. A Clarke, S. T Wang, J Breivik, O Muller, A. R Norman, J. W Arends, M Pauly, D Dillon, H. J. N Andreyev, S. D Finkelstein, A. J Senagore, C. N Hall, K Wilkinson, N Lees, N. R Cruickshank, H. S Goh, D Snary, E Jullian, C Valavanis, L Losi, A Russo, H. M Rabes, J Piris, S Wadler, Y Ono, T Azuma, A Font, C Zietz, M Beranek, J. C Fox, S. A Halter, R Benamouzig, B. R Dix, H Zhang, C Faber, K Omura, V. E Pricolo, C Troungos, K Krtolica, J Benhattar, J. W. C Ho, N. Urosevic, T Lovig, D. P O'Donoghue, J. S Thebo, P De Angelis, J. Q Lee, J Young, Bazan, P Jandik, S Olschwang, S. T Yuen, T Walsh, S Malik, M Tanaka, Kirsten ras mutations in patients with colorectal cancer : the ‘RASCAL II’ study Faculty of Health; Institute of Health and Biomedical Innovation. ,vol. 85, pp. 692- 696 ,(2001)
S Rodenhuis, L Boerrigter, B Top, R J Slebos, W J Mooi, L van't Veer, N van Zandwijk, Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study. Journal of Clinical Oncology. ,vol. 15, pp. 285- 291 ,(1997) , 10.1200/JCO.1997.15.1.285
Wendy De Roock, Derek J. Jonker, Federica Di Nicolantonio, Andrea Sartore-Bianchi, Dongsheng Tu, Salvatore Siena, Simona Lamba, Sabrina Arena, Milo Frattini, Hubert Piessevaux, Eric Van Cutsem, Chris J. O’Callaghan, Shirin Khambata-Ford, John R. Zalcberg, John Simes, Christos S. Karapetis, Alberto Bardelli, Sabine Tejpar, Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab JAMA. ,vol. 304, pp. 1812- 1820 ,(2010) , 10.1001/JAMA.2010.1535
Charles A. Butts, Keyue Ding, Lesley Seymour, Philip Twumasi-Ankrah, Barbara Graham, David Gandara, David H. Johnson, Kenneth A. Kesler, Mark Green, Mark Vincent, Yvon Cormier, Glenwood Goss, Brian Findlay, Michael Johnston, Ming-Sound Tsao, Frances A. Shepherd, Randomized Phase III Trial of Vinorelbine Plus Cisplatin Compared With Observation in Completely Resected Stage IB and II Non–Small-Cell Lung Cancer: Updated Survival Analysis of JBR-10 Journal of Clinical Oncology. ,vol. 28, pp. 29- 34 ,(2010) , 10.1200/JCO.2009.24.0333
Sjoerd Rodenhuis, Robert J. C. Slebos, TherasOncogenes in Human Lung Cancer American Review of Respiratory Disease. ,vol. 142, pp. S27- S30 ,(1990) , 10.1164/AJRCCM/142.6_PT_2.S27
C Mascaux, N Iannino, B Martin, M Paesmans, T Berghmans, M Dusart, A Haller, P Lothaire, A-P Meert, S Noel, J-J Lafitte, J-P Sculier, The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis British Journal of Cancer. ,vol. 92, pp. 131- 139 ,(2005) , 10.1038/SJ.BJC.6602258
Sergio Rizzo, Giuseppe Bronte, Daniele Fanale, Lidia Corsini, Nicola Silvestris, Daniele Santini, Gaspare Gulotta, Viviana Bazan, Nicola Gebbia, Fabio Fulfaro, Antonio Russo, Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy? Cancer Treatment Reviews. ,vol. 36, ,(2010) , 10.1016/S0305-7372(10)70021-9
Gregory J. Riely, Mark G. Kris, Daniel Rosenbaum, Jenifer Marks, Allan Li, Dhananjay A. Chitale, Khedoudja Nafa, Elyn R. Riedel, Meier Hsu, William Pao, Vincent A. Miller, Marc Ladanyi, Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clinical Cancer Research. ,vol. 14, pp. 5731- 5734 ,(2008) , 10.1158/1078-0432.CCR-08-0646
J. J. HARVEY, An Unidentified Virus which causes the Rapid Production of Tumours in Mice Nature. ,vol. 204, pp. 1104- 1105 ,(1964) , 10.1038/2041104B0